<DOC>
	<DOCNO>NCT02563938</DOCNO>
	<brief_summary>This first-in-human study evaluate safety tolerability single dos AK001 across range potentially active dos . Early signal pharmacodynamic activity also evaluate .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics AK001</brief_title>
	<detailed_description>AK001 monoclonal antibody may useful treatment patient severe allergic disease .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>BMI 1830 Determined good health Clinical laboratory value within limit normal value Normal 12lead ECG Stool sample negative parasite Nonsmoker Consumed average 2 drink per day within 6 month Subjects reproductive age must use highly effective method contraception Positive skin test certain cohort Elevated total eosinophil count certain cohort Clinically significant medical history condition laboratory value Receipt investigational drug , biologic medical device within 30 day prior Screening New drug therapy within 1 week study drug administration Antihistamine use within 2 week prior Screening Consumption alcohol within 48 hour study drug administration Positive urine drug test cotinine test Screening Day 1 History , within last 2 year , alcohol abuse , illicit drug use , significant mental illness Demonstration vein unsuitable repeated venipuncture IV infusion Recent treatment alternative therapy may confound clinical laboratory assessment Donation loss 500 mL blood within 56 day prior study drug administration History malignancy within last 5 year History severe allergic anaphylactic reaction Females pregnant breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>